CASRAI Dictionary

Author: MCP Service

  • IRAS PIC Agreement vs CTA: When You Need One

    An IRAS PIC agreement is the contract used when an NHS or HSC organisation’s only role in a study is identifying and directing potential participants to a separate research site — not a full clinical trial agreement (CTA), which governs an organisation actually delivering the protocol. If a site only searches records, sends invitation letters, or passes on contact details without taking consent or running protocol procedures, a PIC agreement — not a CTA or mCTA — is the correct instrument.

    A Participant Identification Centre (PIC) is an NHS or HSC organisation, including an independent contractor of NHS services such as a GP practice, whose only involvement in a research project is processing personal data to identify potential participants and/or direct them to a research site. This article sets out what distinguishes a PIC agreement from a clinical trial agreement, which of the three UK model templates applies, and how to submit one through the Integrated Research Application System (IRAS).

    What is an IRAS PIC agreement?

    An IRAS PIC agreement is a UK model contract governing a Participant Identification Centre — an NHS/HSC organisation that identifies potential research participants and directs them to a separate research site, without undertaking any further research activity itself. Because the PIC processes personal data at the sponsor’s instruction purely to identify or contact potential participants, the agreement establishes a controller/processor relationship and satisfies the data-processing-agreement requirement under GDPR Article 28(3), as confirmed in Health Research Authority (HRA) guidance on UK study-wide governance criteria.

    A PIC is explicitly not a research site. It has no Principal Investigator, no Local Collaborator, and — for non-commercial studies — no Schedule of Events Cost Attribution Tool (SoECAT) or organisation information document requirement, because it carries out no protocol-specified procedures.

    PIC or research site — how do you tell the difference?

    The dividing line is activity, not intention. An organisation is acting as a PIC when it searches records against eligibility criteria and directs interested individuals elsewhere. It becomes a research site the moment it takes informed consent, performs a protocol-specified assessment (such as a screening blood test), or delivers any procedure requiring Principal Investigator oversight.

    Activity PIC role Research site role
    Search patient records against protocol eligibility criteria Yes Yes
    Send an invitation letter or outline participant information sheet Yes Yes
    Obtain informed consent to participate in the study No Yes
    Carry out a protocol-specified screening procedure No Yes
    Require a Principal Investigator No Yes

    A single legal entity cannot be both a PIC and a site for the same project at the same time — if identification activity sits within the same organisation delivering the research, the whole entity is treated as a research site and no PIC agreement is possible.

    IRAS PIC agreement vs a full CTA or mCTA: what changes?

    A clinical trial agreement (CTA), including the model Clinical Trial Agreement (mCTA) and its CRO variant, is a comprehensive contract covering the entire delivery of a study at a site: consent, protocol procedures, budget, indemnity, and Good Clinical Practice compliance. A PIC agreement covers a single, narrow function — recruitment support — and carries none of the delivery, indemnity, or capacity-and-capability obligations that a CTA requires.

    Feature IRAS PIC agreement CTA / mCTA
    Scope Identification and referral of participants only Full protocol delivery at a research site
    Legal basis Data controller/processor agreement (GDPR Art. 28(3)) Research delivery contract with indemnity and GCP obligations
    Principal Investigator required No Yes
    SoECAT / cost attribution Not required (non-commercial) Required (non-commercial)
    IRAS form question A73 (non-CTIMP) or cover letter for CTIMPs (A3) Standard site declaration

    Getting this wrong in either direction has consequences. Treating a recruitment-only site as a full CTA site over-engineers governance and delays set-up; treating an organisation that actually takes consent as a PIC understates its regulatory role and risks a governance breach — an amendment is required to reclassify a PIC as a research site, or a site as a PIC, once a project is already approved.

    Which of the three model PIC agreement templates applies?

    The UK’s Four Nations Contracts Leads maintain three template PIC agreements, published on the IRAS website. Choosing the wrong one is the most common set-up error research offices report.

    • Commercial Site-to-PIC agreement — used when a commercial sponsor’s contracted research site sub-contracts identification activity to a PIC; creates a controller/processor/sub-processor chain between sponsor, site, and PIC.
    • Non-commercial Site-to-PIC agreement (mNC-PICA site-to-PIC) — used when a non-commercial research site delegates identification to a PIC on the sponsor’s behalf.
    • Non-commercial Sponsor-to-PIC agreement (mNC-PICA sponsor-to-PIC) — used when a non-commercial sponsor contracts directly with the PIC, which is possible even where the only NHS/HSC role in the entire project is that of a PIC.

    For commercial contract research, the HRA’s National Directive on Commercial Contract Research sets a policy mandate that only the appropriate, unmodified UK template agreement is used. A waiver to depart from the template is rarely granted, is liable to add months of central negotiation, and — even where agreed — only removes the obligation on the participating organisation to accept the template unmodified.

    Setting up and submitting a PIC agreement in IRAS

    PIC arrangements must be declared in the IRAS form itself, not left to a side letter. For non-CTIMP studies, sponsors answer yes to question A73 to reveal the secondary PIC fields and enter contact details and activities for each PIC. For CTIMPs, sponsors answer yes to question A3 and list PICs already identified in a cover letter rather than in the form.

    Only the Word version of the PIC agreement should be submitted for review — not a PDF — so reviewers can compare it against the model template and confirm it is unmodified. The agreement does not need to be signed, or to carry a completed financial appendix or project support arrangements schedule, at the point of IRAS submission; it should be signed once the PIC is ready to begin identification activity and the site it supports has itself entered into an agreement.

    PIC activity can only start once every one of these three conditions is met, and the specific approval body depends on nation:

    • England and Wales — HRA and HCRW Approval issued, capacity and capability confirmed at the supported research site, and a signed PIC agreement in place.
    • Northern Ireland — HSC RD Approvals issued, capacity and capability confirmed, and a signed agreement with the HSC organisation acting as PIC.
    • Scotland — NHS R&D permission granted at both the research site and the PIC site, and a signed agreement in place.

    Answer-first Q&A

    What is a PIC agreement?

    A PIC agreement is a data-processing contract between a sponsor (or site) and an NHS/HSC organisation that identifies potential participants on the sponsor’s behalf. It establishes a controller/processor relationship under GDPR Article 28(3) and is used only where the organisation directs participants elsewhere without carrying out research activity itself.

    What is the model commercial chief investigator agreement?

    The model Commercial Chief Investigator Agreement (mCCIA) is a separate UK template used between a commercial sponsor and the NHS/HSC organisation employing the study’s Chief Investigator, with a CRO variant (mCCIA-CRO) where a clinical research organisation is a third party. It is unrelated to PIC status and applies only where an individual holds the Chief Investigator role.

    What are PIC sites in clinical trials?

    PIC sites are NHS/HSC organisations — Trusts, Boards, or independent primary care contractors such as GP practices — whose sole role in a trial is identifying and directing potential participants. They are excluded from receiving the full UK Local Information Pack and do not require a Principal Investigator, receiving instead only the documents relevant to their identification function.

    Implications for research offices

    Correctly classifying a site as a PIC rather than a research site — or vice versa — determines which template applies, whether a Principal Investigator and SoECAT are needed, and which IRAS form question captures the arrangement. Sponsors should decide PIC use at the feasibility stage and document each PIC’s proposed activity precisely in the IRAS form. As multi-site, recruitment-heavy designs become more common in UK research administration practice, getting this classification right at set-up avoids the amendment cycle that reclassification after approval requires.

  • MNCA Template: 2026 UK Non-Commercial Agreement

    The MNCA template is the UK-wide Model Non-Commercial Agreement published on the Integrated Research Application System (IRAS), used by non-commercial sponsors — universities, NHS trusts, and charities — to confirm a participating NHS or HSC organisation’s capacity and capability to deliver a non-commercial interventional study, and it must be used unmodified except for its yellow-highlighted schedule fields.

    The Model Non-Commercial Agreement (MNCA) is a standardised contract between a non-commercial research sponsor and each NHS or HSC organisation participating in a study, distinct from the model Clinical Trial Agreement (mCTA) used for commercially sponsored trials. Research offices searching for the current version need to know not only where to find it, but when it applies, how it differs from its commercial counterpart, and what changed in the April 2026 update to the UK’s suite of model agreements.

    What Is the MNCA (Model Non-Commercial Agreement)?

    The mNCA was first published in 2008 by the UK Clinical Research Collaboration to remove the need for bespoke legal negotiation on every non-commercial study site. It sets out the responsibilities of the sponsor and the NHS or HSC organisation, including indemnity, data protection, intellectual property, and governance oversight, in a single UK-wide template.

    “Non-commercial” in this context describes the sponsorship arrangement, not the funding source: a study funded in part by a commercial entity but sponsored by a university, NHS trust, government department, or Research Council still uses the mNCA rather than the mCTA. The agreement covers interventional research, including clinical trials of investigational medicinal products (CTIMPs), medical device studies, and other interventional designs such as trials of surgical technique.

    MNCA vs mCTA: How Do the Two Agreements Differ?

    The core distinction is sponsorship type. The mNCA applies to non-commercial sponsors; the mCTA (model Clinical Trial Agreement) applies to commercially sponsored trials, typically run by pharmaceutical or biopharmaceutical companies, and was originally developed through a Department of Health and Association of the British Pharmaceutical Industry (ABPI) collaboration. Both sit within a wider suite of UK model agreements maintained for use across all four nations.

    Agreement Full name Typical sponsor
    mNCA Model Non-Commercial Agreement University, NHS trust, charity, Research Council
    mCTA / CRO-mCTA Model Clinical Trial Agreement Pharmaceutical or biopharmaceutical company
    mCCIA / CRO-mCCIA Model Commercial Chief Investigator Agreement Commercial sponsor, with an NHS-employed chief investigator
    mCIA / CRO-mCIA Model Clinical Investigation Agreement Commercial sponsor of a medical device investigation
    mNISA / CRO-mNISA Model Non-Interventional Study Agreement Commercial sponsor of a non-interventional study

    When Must Institutions Use the Unmodified MNCA?

    For commercial contract research, the Health Research Authority’s National Directive on Commercial Contract Research makes use of the unmodified UK template agreements a formal policy mandate, and HRA and HCRW Approval are usually issued conditionally on that use. Non-commercial research carries a materially lighter obligation: there is no equivalent directive, only a policy expectation that the appropriate unmodified template is used, and departing from it risks prolonged central and site-level review rather than automatic non-approval.

    Waivers to use a modified or bespoke agreement are possible in either case but are granted only in exceptional circumstances, generally where no UK template exists for the project type. A waiver request can add many months to study set-up and, according to the HRA, is unlikely to be agreed.

    What Changed in the April 2026 Model Agreement Update?

    Updated versions of the mNCA, alongside the mCTA, mCCIA, mCIA, mNISA and the hub-and-spoke agreements, came into use on 28 April 2026, the date the reformed UK clinical trials regulations for CTIMPs took effect, alongside separate policy changes affecting non-CTIMP studies. According to the Health Research Authority, new studies submitted through IRAS on or after that date must use the April 2026 versions; earlier versions are no longer accepted for new submissions.

    Existing contracts already in place do not need to be reissued. Any new contract entered into with a participating NHS or HSC organisation from 28 April 2026 onward, however, must use the current version. The Four Nations Contracting Leads group, which oversees the model agreement suite across England, Scotland, Wales and Northern Ireland, reviews feedback and considers further amendments roughly every six months, so research offices should treat “the current mNCA” as a version that moves rather than a fixed document.

    Where the MNCA Fits Among Other IRAS Model Agreements

    Several related, non-commercial documents sit alongside the full mNCA and are easily confused with it:

    • Organisation Information Document (OID) — a lighter-weight document used for non-commercially sponsored projects at sites where a full contract is not proportionate, recording site-specific arrangements rather than standalone legal terms.
    • IRAS PIC agreement — used where a site acts only as a Participant Identification Centre, referring or identifying potential participants without delivering study procedures itself, so it carries narrower obligations than the mNCA.
    • Model non-commercial hub and spoke agreement — used where one NHS organisation coordinates delivery across several satellite sites for a single non-commercial study.

    Choosing the wrong document among these is one of the most common causes of delay at site set-up, since each is reviewed against different assessment criteria under HRA and HCRW Approval.

    Frequently Asked Questions

    What is an mNCA?

    The mNCA is the UK-wide template contract used between a non-commercial research sponsor and a participating NHS or HSC organisation. It confirms the site’s capacity and capability to deliver the study and is expected to be used without modification beyond its highlighted schedule sections.

    What is the model commercial chief investigator agreement?

    The mCCIA is used where a commercial sponsor engages a chief investigator who is employed by an NHS or HSC organisation, rather than contracting the organisation itself as the delivery site. A CRO-mCCIA variant adds a contract research organisation as a third party.

    What is the Organisation Information Document?

    The Organisation Information Document (OID) is shared with participating NHS and HSC organisations as part of the local information pack for non-commercial studies. It records agreed site arrangements and, in some cases, doubles as the contract for the study rather than sitting alongside a separate mNCA.

    What This Means for Research Offices

    The practical implication of the April 2026 update is version control, not new legal risk: institutions that continue using pre-2026 mNCA templates for new IRAS submissions will have them rejected at validation, adding avoidable delay to study set-up. Research offices should build a routine check of the IRAS templates page into contract-issuing workflows, since the Four Nations Contracting Leads group’s six-monthly review cycle means further updates are a standing possibility rather than a one-off event.

    More broadly, the mNCA’s “unmodified template plus policy expectation” model reflects a wider shift in research administration toward standardised, negotiation-light contracting — the same logic that underpins standardised data-sharing agreements and role-attribution frameworks elsewhere in the research lifecycle. Institutions that treat the mNCA as a living document, tied to the regulatory calendar rather than a static PDF, will spend less time in central review and more time delivering studies. Research offices building out an internal glossary of contracting and governance terms alongside the mNCA may also find it useful to cross-reference the CASRAI Dictionary for related research-administration terminology.

  • Model Clinical Trial Agreement UK Guide (2026)

    The UK Model Clinical Trial Agreement (mCTA) is the standard contract template that commercial sponsors and NHS or HSC organisations use to set up an industry-sponsored clinical trial, published and maintained via the Health Research Authority’s IRAS toolkit, and required to be used unmodified in almost all cases across England, Scotland, Wales and Northern Ireland. The model clinical trial agreement UK framework now covers seven distinct template families, from the core mCTA to devices, primary care and non-commercial variants, and the whole suite was refreshed on 28 April 2026.

    In plain terms: the mCTA is a UK-wide, sector-agreed contract — not a bespoke negotiation — that fixes the legal, indemnity and financial terms between a trial sponsor (or its contract research organisation) and each participating NHS or HSC site, so that individual hospitals and trusts do not have to negotiate contract wording study by study.

    What is the UK Model Clinical Trial Agreement (mCTA)?

    The mCTA is the default site agreement for commercial, industry-sponsored clinical trials of investigational medicinal products (CTIMPs) run in NHS and HSC organisations. It sits alongside a wider family of UK model agreements covering devices, primary care, non-interventional studies and non-commercial research, all hosted on the Integrated Research Application System (IRAS) website.

    Under the current suite, published for use from 28 April 2026, the seven core template families are:

    Template Typical use case Current version
    mCTA / CRO-mCTA Industry-sponsored CTIMP trials in NHS/HSC hospitals April 2026
    ATMP-mCTA / CRO-ATMP-mCTA Trials of investigational advanced therapy medicinal products April 2026
    Primary care mCTA (bi- and tri-partite) Industry trials run through GP practices and other primary care sites April 2026
    mCIA / CRO-mCIA Commercial medical device clinical investigations April 2026
    mNISA / CRO-mNISA Commercial non-interventional studies April 2026
    mNCA Non-commercial interventional research (trials, devices, tissue, data) April 2026
    mCCIA / CRO-mCCIA Contracting an NHS/HSC employee as Chief Investigator April 2026

    Each template is designed to be used without alteration, with only the yellow-highlighted, study-specific fields completed. This is what allows an mCTA-based site agreement to be executed in days rather than the weeks or months a fully bespoke contract typically takes to negotiate clause by clause.

    ABPI model clinical trial agreement vs HRA model clinical trial agreement

    Sponsors and R&D teams search for both the “ABPI model clinical trial agreement” and the “HRA model clinical trial agreement” — but these are not two competing templates. They are the same lineage of document, described by its origin on one hand and its current steward on the other.

    The original CRO-mCTA guidance describes how the tripartite template was developed jointly as the “NHS-ABPI-BIA Contract Research Organisation model Clinical Trial Agreement”, reflecting the historic partnership between the NHS, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA). That is why many sponsors still call it the “ABPI mCTA” out of habit.

    Today, the templates are published, version-controlled and hosted through the Health Research Authority’s IRAS toolkit, and governed by the UK Four Nations Contracting Leads Group, which reviews user feedback and decides on revisions roughly every six months. That governance and hosting arrangement is why the same document is now more accurately described as the “HRA model clinical trial agreement”. There is one current mCTA family, not a rival ABPI version and a rival HRA version to choose between.

    When to use the unmodified mCTA vs a bespoke agreement

    For nearly all commercial contract research, the unmodified UK template is mandatory, not optional. Under the National Directive on Commercial Contract Research, HRA and Health and Care Research Wales (HCRW) Approval is normally issued conditionally on the appropriate, unaltered template being used, and each devolved nation applies an equivalent policy position.

    A bespoke or modified agreement is reserved for genuinely exceptional circumstances, primarily where no UK template exists for the specific project type. Sponsors who want to depart from the standard template must:

    • Submit a formal waiver request to the HRA and HCRW, usually as part of the Approval conditions
    • Set out any proposed changes clearly in the IRAS cover letter, with a tracked-change version of the template
    • Provide a detailed, change-by-change rationale for each deviation

    The HRA is explicit that a waiver request is “liable to add many months of central negotiation” and is unlikely to be agreed. Even where a waiver is granted, it only removes the obligation on participating NHS or HSC organisations to accept the unmodified template — individual sites remain free to propose their own terms or seek independent legal advice at the sponsor’s expense. For non-commercial research there is no equivalent statutory directive, but the same policy expectation applies: use the appropriate UK template (typically the mNCA) unmodified, or expect a prolonged review.

    How the HRA and IRAS toolkit route studies to the right template

    Sponsors do not have to guess which agreement applies. For studies going through HRA and HCRW Approval, the HRA Initial Assessment Letter and the subsequent Approval letter specify the correct agreement for each participating site type — whether that is an unmodified mCTA variant or an Organisation Information Document for non-commercial studies.

    Two toolkits sit either side of that decision:

    • The IRAS website (myresearchproject.org.uk) hosts the live template documents, version-dated guidance notes, and the definitive “Templates for supporting documents” index used to download the correct .docx file
    • The Clinical Trials Toolkit (ct-toolkit.ac.uk), a UKCRC-supported routemap, walks research teams through the contracting decision points step by step, from identifying sponsorship type to selecting the matching agreement

    Where a study uses a hub-and-spoke delivery model, a further layer applies: the Lead Trial Site contracts with the sponsor via an unaltered mCTA or mNCA, and then a UK template Hub and Spoke Agreement subcontracts rights and responsibilities down to each Other Trial Site. Feedback on any template is directed to the Four Nations Contracting Leads Group via [email protected], and any new studies submitted in IRAS on or after 28 April 2026 must use the April 2026 versions — earlier versions are no longer accepted.

    Frequently asked questions

    What is a clinical trial agreement?

    A clinical trial agreement is a legally binding contract between a trial sponsor, a research site and (in some templates) the principal investigator, setting out each party’s responsibilities, indemnities and financial terms for a specific study. In the UK, most industry-sponsored trials use a standard mCTA rather than a one-off negotiated contract.

    What is the NHS model CDA?

    The model Confidentiality Disclosure Agreement (mCDA) is a separate UK-wide template used earlier in study set-up, before a site agreement such as the mCTA is signed. It governs the sharing of confidential feasibility information between a sponsor and prospective NHS or HSC sites, and — like the mCTA — is expected to be used unaltered.

    Implications and outlook for sponsors and R&D offices

    The practical implication for institutional research offices is straightforward: default to the unmodified template every time, budget waiver requests as a last resort measured in months rather than weeks, and rebuild any local contract-tracking spreadsheets around the April 2026 version numbers so that expired templates are not accidentally resubmitted through IRAS.

    Because the Four Nations Contracting Leads Group reviews feedback and revises the suite roughly twice a year, sponsors and R&D offices operating in research administration functions should treat the mCTA suite as a living document set, not a one-off download, and check the IRAS templates page before every new study submission rather than relying on a cached copy from a previous trial.

  • Clinical Trial Agreements Explained: Structure, Parties and Sign-Off

    A clinical trial agreement (CTA) is the legally binding contract that fixes how a trial will run, who pays for what, who owns any resulting intellectual property, and who carries liability if something goes wrong. It is negotiated between the sponsor (or its contract research organisation) and the research site, and it must be fully executed before the first participant is recruited.

    A clinical trial agreement is the contract that allocates the legal, financial and operational responsibilities for conducting a specific clinical study between a sponsor and a research institution or investigator. Research administrators new to clinical contracting encounter the CTA as the single document that everything else — costings, indemnity cover, publication clearance, data ownership — hangs off.

    What is a clinical trial agreement?

    A clinical trial agreement is a written contract, not a protocol or an ethics approval. It sits alongside — but is legally distinct from — the study protocol, the participant information sheet, and any regulatory or ethics sign-off. Its function is purely contractual: it converts the scientific plan for a trial into binding obligations that a court could enforce.

    Every jurisdiction that runs interventional trials of medicinal products requires one. In the UK, a CTA (or its non-commercial equivalent) must be in place before a site can open to recruitment under the UK Clinical Trials Regulations, and the Health Research Authority treats a missing or incomplete agreement as a start-up blocker, not a formality to be finished later.

    Who are the parties to a clinical trial agreement?

    Most CTAs involve three or four distinct parties, each with a different legal interest in the trial. The sponsor initiates, funds and takes overall responsibility for the trial; the research site (a hospital, university, or NHS trust) hosts the study and employs the staff who run it; and the principal investigator is the named clinician or academic accountable for day-to-day conduct at that site.

    • Sponsor — a pharmaceutical, biotech or medical device company, or an academic institution acting as sponsor for investigator-led research.
    • Contract research organisation (CRO) — frequently contracted by the sponsor to manage set-up, monitoring and payments; in tripartite UK model agreements, the CRO can be a direct signatory alongside the sponsor and the site.
    • Research site / host institution — the legal entity (NHS trust, university, or independent hospital) that signs on behalf of the department running the study.
    • Principal investigator — named in the agreement but usually not a contracting party in their personal capacity; their obligations run through their employing institution.

    The CITI Program summarises the arrangement precisely: a CTA “serves as a legally binding contract between a sponsor, site, and researcher, and outlines each party’s responsibilities and obligations for the clinical trial.”

    What clauses does a clinical trial agreement cover?

    A CTA is built from a fixed set of recurring clauses, and administrators new to the process should expect negotiation to concentrate almost entirely on four of them: indemnity, intellectual property, publication rights, and data/record access. The rest are usually more mechanical.

    Clause What it fixes Typical friction point
    Indemnity and insurance Who compensates whom for harm, negligence, or breach Sponsor indemnity wording vs institutional NHS indemnity schemes
    Intellectual property Ownership of background IP vs new inventions arising from the trial Background IP retained by originating party; foreground IP terms vary by contract type
    Publication rights When and how results may be published or presented Sponsor review period vs researcher’s right to publish negative results
    Confidentiality Protection of proprietary protocols, data and trial materials Duration of confidentiality obligations after trial closure
    Financial terms Budget, payment schedule, and cost recovery Per-patient costs vs milestone-linked payment triggers
    Data and record-keeping Access, retention and audit rights over trial records Regulatory retention periods vs institutional data-governance policy
    Subject injury Care and compensation for participants harmed by the trial Allocation of liability between sponsor and clinical negligence cover

    Peer-reviewed research backs up why these clauses matter operationally, not just legally: a quantitative study published via Cambridge Core (Lawrence et al.) found that standardised agreement templates measurably reduce multisite trial start-up time compared with bespoke, clause-by-clause negotiation.

    Commercial CTA or non-commercial agreement — which applies?

    Which template an administrator reaches for depends on who is funding the trial, not on the disease area or design. This distinction is UK-specific but the underlying logic — industry-funded work uses a different contracting route to grant-funded academic work — recurs across most national research systems.

    Feature Model Clinical Trial Agreement (mCTA) Model Non-Commercial Agreement (mNCA)
    Funder Pharmaceutical, biotech or device company Grant body, charity, or NIHR/UKRI funding
    Publisher ABPI / HRA UK-wide model suite UK-wide non-commercial model agreement suite
    IP default position Sponsor typically retains foreground IP Host institution typically retains IP
    Common signatories Sponsor, CRO, NHS trust Funder, NHS trust, sometimes co-sponsoring university

    The Health Research Authority confirmed on 28 April 2026 that it had issued an updated suite of UK model agreements to reflect changes to the UK Clinical Trials Regulations, covering both commercial and non-commercial templates. The NIHR confirms that model agreements are one of the UK-wide tools institutions use alongside the National Contract Value Review when setting per-patient trial costs. The Association of the British Pharmaceutical Industry separately maintains a tripartite Model Generic Clinical Trial Agreement for industry-sponsored research delivered through NHS hospitals and managed by CROs.

    How is a CTA negotiated and signed off?

    Sign-off follows a predictable sequence: the sponsor or CRO issues a draft (usually a model agreement where one applies), the institution’s research and innovation office reviews it against institutional policy, legal counsel on both sides negotiate the contested clauses, and the agreement is executed by an authorised signatory at the institution — rarely the investigator personally.

    • Draft issued, typically based on a national model template where the funder type allows it.
    • Institutional review against local indemnity, IP and data-governance policy.
    • Negotiation of contested clauses — indemnity and publication rights are the most common sticking points.
    • Legal execution by the institution’s authorised signatory, not the principal investigator.
    • Filing alongside ethics approval and regulatory documentation before site activation.

    Using an unamended model agreement removes most of this negotiation entirely, which is precisely why the HRA and NIHR continue to maintain and update the UK-wide model suite rather than leaving every trial to bespoke drafting.

    Common questions on clinical trial agreements

    What is a clinical trials agreement?

    A clinical trials agreement is a legally binding contract between a sponsor, a research site and an investigator that fixes each party’s responsibilities before a study begins. It covers funding, indemnity, intellectual property, publication rights and data access, and must be executed before recruitment starts.

    What is the difference between a CTA and a CRA?

    A CTA (clinical trial agreement) is the contract governing a study; a CRA (clinical research associate) is a person who monitors trial conduct and compliance at sites. One is a legal document; the other is a job role responsible for oversight and monitoring within the trial.

    Who develops the clinical trial agreement?

    The sponsor or its CRO typically issues the first draft, often a national model agreement where one is available for the funding type. The host institution’s research office and legal counsel then negotiate amendments before an authorised institutional signatory executes the final version.

    What this means for research administrators

    The direction of travel in the UK is towards standardisation, not bespoke drafting. The HRA’s April 2026 update to the model agreement suite, and the NIHR’s continued linkage of model contracts to the National Contract Value Review, push institutions towards unamended templates as the default and bespoke drafting as the justified exception.

    The practical takeaway: identify the funding type first — commercial sponsor versus non-commercial funder — before selecting a template, route indemnity and publication-rights clauses to legal review early, and treat the CTA as a live governance document, filed and retrievable alongside ethics approval for the trial’s life, not a one-off signing formality.

    The CTA sits within a wider set of research administration obligations spanning ethics, finance and compliance sign-off — treating it in isolation from that broader governance process is the most common source of late-stage delay.

  • When Is a Material Transfer Agreement Required? A Decision Framework

    A material transfer agreement is required whenever tangible, non-public research materials — cell lines, plasmids, antibodies, reagents, transgenic organisms, or associated data — move between two separate legal entities and the provider wants to retain ownership, control future use, or protect intellectual property. If the material is freely purchasable on the open market, or if it never leaves the same legal entity, no material transfer agreement is needed. Between those two extremes sits a middle case — a simple loan or implementing letter — that many institutions handle incorrectly, which is the gap this framework closes.

    A material transfer agreement (MTA) is a legally binding contract that sets out the terms under which tangible research materials are supplied by one organisation (the provider) and used by another (the recipient), covering ownership, permitted use, publication rights, liability, and the treatment of any resulting inventions.

    Contents

    What is a material transfer agreement?

    A material transfer agreement is the contract vehicle research institutions use to move physical research materials — rather than data or funding — between organisations while preserving each party’s rights. It typically fixes four things: who owns the original material, what the recipient may do with it, who owns anything invented using it, and whether results can be published without restriction.

    MTAs sit alongside, but are distinct from, confidentiality agreements and sponsored-research agreements. A confidentiality agreement protects information; an MTA protects a physical or biological thing. Where data accompanies the material — sequencing reads, patient metadata, assay results — many institutions issue a linked Data Transfer Agreement (DTA) rather than folding data terms into the MTA itself.

    When is a material transfer agreement required?

    An MTA is required whenever three conditions are all true: the item is tangible (not purely information), it is not freely available for anyone to buy, and the provider wants to attach conditions to its use. Absent any one of those three, a lighter mechanism — or nothing — usually suffices.

    The general triggers

    Institutions typically require a full MTA for: proprietary cell lines and plasmids; genetically modified organisms; patient- or human-derived samples; antibodies or reagents developed in-house; software tied to physical hardware; and any material being sent to, or received from, a for-profit company. The University of Manchester’s contracts team states plainly that an MTA is required for the transfer of materials and/or data between the University and a third party, but explicitly carves out one exception: if the materials are available to purchase on the open market, an MTA will not be required, because that transaction is simply a purchase handled through procurement.

    Special categories that raise the bar

    Three categories demand extra scrutiny before any material moves, regardless of how “routine” the transfer feels:

    • Human-derived material — samples covered by the UK Human Tissue Act 2004 require Human Tissue Authority (HTA) licensing checks and research ethics approval before any transfer agreement is signed.
    • Genetic resources sourced internationally — transfers of genetic material obtained from a provider country after the Nagoya Protocol entered into force in 2014 trigger access-and-benefit-sharing (ABS) obligations under the Convention on Biological Diversity, independent of whatever the MTA itself says.
    • Plant genetic resources for food and agriculture — material listed under the Multilateral System of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA, in force since 2004) must move under the FAO’s Standard Material Transfer Agreement (SMTA), a fixed-form contract that cannot be substituted with an institution’s own template.

    Materials crossing borders may also need export-control clearance where dual-use or sensitive technology is involved, and third-party funding terms must be checked for conflicts before an MTA is countersigned — a funder’s data-sharing mandate can directly contradict a provider’s proposed use restrictions.

    The decision framework: full MTA, simple letter, or no agreement

    Most guidance treats “do I need an MTA” as binary. In practice, research offices work with three tiers, and choosing the wrong one either creates unnecessary friction or leaves an institution legally exposed.

    Scenario Mechanism Why
    Unmodified biological material moving between two non-profit institutions that are both signatories to a master agreement Simple implementing/loan letter Terms are pre-agreed once; each transfer just references the master deal, e.g. under the NIH-developed Uniform Biological Material Transfer Agreement (UBMTA)
    Proprietary, modified, human-derived, or export-controlled material; any transfer involving a for-profit party Full negotiated MTA Ownership, publication rights, IP on improvements, and liability all need bespoke terms
    Material freely available for purchase on the open market, or moving within the same legal entity No agreement (procurement or internal process only) There is no proprietary right or cross-entity risk to allocate
    Plant genetic resources under the ITPGRFA Multilateral System FAO Standard Material Transfer Agreement (SMTA) A treaty-mandated fixed form; institutions cannot substitute their own template

    The middle tier is the one most frequently mishandled. Under the UBMTA — a master agreement developed under the auspices of the US National Institutes of Health in 1995 — signatory institutions exchange unmodified biological materials using a one-page implementing letter instead of renegotiating terms each time. But even under UBMTA cover, a full bespoke MTA is still required the moment the material is human-derived, genetically modified, or hazardous, or if either party is not a signatory.

    Practically, ask four questions in order:

    1. Is the material purchasable off the shelf? If yes, stop — use procurement, not an MTA.
    2. Does a signed master agreement (e.g. UBMTA) already cover both institutions and this exact material type unmodified? If yes, a loan/implementing letter is sufficient.
    3. Is either party for-profit, or is the material modified, human-derived, genetically modified, or export-controlled? If yes, a full negotiated MTA is required.
    4. Is the material a plant genetic resource under the ITPGRFA Multilateral System? If yes, the FAO SMTA applies and overrides institutional templates.

    Answer-first Q&A

    Do I need an MTA?

    You need an MTA if you are sending or receiving tangible, non-public research material — biological samples, reagents, cell lines, or similar — to or from a different legal entity. If the material is commercially purchasable or stays within your own institution, no agreement is required; check with your contracts office before assuming either way.

    What is a material transfer agreement?

    A material transfer agreement is a contract between a provider and a recipient organisation that documents the material being transferred and the terms governing its ownership, permitted use, publication, and any resulting inventions. It protects both parties’ intellectual property and clarifies liability before materials change hands.

    What is the standard material transfer agreement (SMTA)?

    The Standard Material Transfer Agreement is the fixed-form contract required under the FAO’s International Treaty on Plant Genetic Resources for Food and Agriculture. It governs transfers of listed plant genetic resources within the treaty’s Multilateral System and cannot be replaced by an institution’s own MTA template.

    Why do institutions require an MTA?

    Institutions require an MTA to protect ownership of proprietary materials, define permitted research use, and settle publication and inventorship rights in advance. Without one, disputes over who owns follow-on discoveries or who may publish first become far harder to resolve after the fact.

    Implications for research administrators

    Getting the tier wrong has real cost on both sides. Forcing every transfer through a full negotiated MTA slows down routine science and burdens contracts teams already stretched thin. Skipping an agreement where one is legally required — particularly for human-derived or export-controlled material — exposes the institution to compliance action and jeopardises the researcher’s ability to publish or patent.

    A working checklist for any incoming or outgoing transfer should confirm: the material’s category (unmodified biological, modified, human-derived, genetic resource, software, data); whether either party is for-profit; whether a signatory master agreement already applies; whether human tissue, Nagoya Protocol, or export-control obligations attach; and who at the institution holds authority to sign, since most universities restrict MTA signature to a small number of authorised contracts officers rather than the individual researcher.

    As research materials increasingly cross borders and sectors — biobanks, industry-academic partnerships, international consortia — the three-tier framework above gives administrators a faster, defensible route to the right mechanism, rather than defaulting every transfer to the slowest, most conservative option. For related definitions and terminology used across research administration, see the CASRAI Dictionary and the broader research administration resource hub.

  • Material Transfer Agreement: A UK & US Guide for Research Administrators

    A material transfer agreement is the legal contract that must be signed before tangible research materials — cell lines, reagents, biological samples, software, or datasets — move between two organisations. It fixes who owns the material and any derivatives, sets what the recipient may do with it, and allocates liability. A material transfer agreement (MTA) is required whenever proprietary or regulated research material crosses an institutional boundary, whether between two universities, from academia to industry, or the reverse.

    Definition: a material transfer agreement is a contract that governs the transfer of tangible research materials between two organisations when the recipient intends to use the material for their own research purposes.

    Jump to:

    What is a material transfer agreement?

    A material transfer agreement sits between two parties: a provider, who supplies the material, and a recipient, who receives it for research, testing, or evaluation. Almost no research organisation will release physical material — a plasmid, an antibody, a chemical compound, a mouse line, patient-derived tissue, or bundled software and data — without one in place.

    Three types of MTA are most common at academic institutions: transfers between academic or research institutions, transfers from academia to industry, and transfers from industry to academia. Each carries different negotiating priorities, since a commercial provider will typically restrict use and reserve rights over derivatives more tightly than a non-profit research institute would.

    When is a material transfer agreement required?

    An MTA is required whenever material is not already covered by a broader collaboration agreement, consortium agreement, or funding contract that addresses ownership and use of transferred materials. It becomes mandatory, rather than merely advisable, in three recurring situations.

    • Human tissue transfers: in the UK, transfer of human tissue or cells for research is governed by the Human Tissue Act 2006, and an MTA (or equivalent material transfer form) is needed to evidence lawful, consented use and to satisfy Human Tissue Authority licensing conditions.
    • Materials with commercial or patent potential: where the material, or a discovery derived from it, could be patented, an MTA is used to fix inventorship, licensing, and revenue-sharing terms before any transfer takes place.
    • Cross-institutional research collaborations: whenever a researcher sends or receives compounds, cell lines, reagents, or proprietary datasets from an external organisation without an overarching agreement already in force.

    Institutional practice is consistent on one point: individual principal investigators cannot sign MTAs on behalf of their university. UK universities route requests through a research contracts or Research and Innovation Services (RIS) office; US institutions route them through a Technology Transfer Office (TTO). This centralisation protects the institution’s intellectual property position and ensures the agreement is enforceable.

    What clauses does a standard MTA contain?

    Most MTAs, regardless of jurisdiction, follow a recognisable clause structure. Understanding this structure is the fastest way for a research administrator to review a third-party MTA against institutional norms rather than starting from a blank page.

    • Permitted use: restricts the material to a defined research purpose, typically excluding commercial use, further distribution, or use in human subjects without separate approval.
    • Ownership and derivatives: confirms the provider retains ownership of the original material, and defines who owns modifications, progeny, and unmodified derivatives.
    • Intellectual property and inventions: allocates rights over any patentable invention arising from use of the material, often with a first option to license back to the provider.
    • Publication rights: preserves the recipient’s right to publish results, sometimes subject to a short pre-publication review period for the provider to flag confidential information.
    • Confidentiality: protects any proprietary information disclosed alongside the material.
    • Warranties, indemnities and liability: the provider typically disclaims warranties on the material’s fitness for purpose and safety, while the recipient indemnifies the provider against misuse.
    • Term, termination and disposition: specifies how long the agreement runs, and whether unused material must be returned or destroyed at the end of the project.

    These clauses collectively protect the parties’ research and commercial interests in the material while ensuring compliance with applicable regulatory requirements, from data protection through to biosafety.

    How does UK practice differ from US practice?

    The underlying clause structure is similar on both sides of the Atlantic, but the institutional machinery around MTAs differs in three practical respects: which model agreement negotiators start from, which office holds signing authority, and which professional body supports that office.

    Aspect UK practice US practice
    Model agreement Lambert Toolkit model materials transfer agreements, published by the UK Intellectual Property Office Uniform Biological Material Transfer Agreement (UBMTA), developed by the National Institutes of Health (NIH)
    Signing authority University Research and Innovation Services / research contracts team Institutional Technology Transfer Office (TTO)
    Human tissue regulation Human Tissue Act 2006, overseen by the Human Tissue Authority Institutional Review Board (IRB) oversight under the federal Common Rule
    Professional body ARMA (Association of Research Managers and Administrators) NCURA (National Council of University Research Administrators) and AUTM
    Template repository ARMA’s published MTA templates, including a non-human tissue MTA AUTM’s MTA toolkit and public list of UBMTA signatory institutions

    The UBMTA is a master agreement: once a US institution signs it, subsequent transfers between fellow signatories only require a short implementing letter rather than a fresh negotiation, which is why AUTM’s signatory list matters operationally. The UK has no single equivalent master agreement; Lambert Toolkit models function as drafting templates rather than a pre-signed master framework, so each UK MTA is typically negotiated afresh, even between repeat institutional partners. ARMA, NCURA, and their European counterpart EARMA are all national associations affiliated to INORMS, the International Network of Research Management Societies, reflecting how widely MTA negotiation sits within the research administration profession globally.

    Material transfer agreement FAQs

    What is a material transfer agreement?

    A material transfer agreement is a contract that governs the transfer of tangible research materials — such as reagents, cell lines, plasmids, vectors, chemical compounds, or software — between two organisations when the recipient intends to use the material for its own research purposes.

    What is the difference between MTA and NDA?

    An MTA governs the physical transfer of tangible material and covers ownership, permitted use, and derivatives, while a non-disclosure agreement (NDA) governs only the confidentiality of shared information. Many MTAs incorporate confidentiality terms directly, making a separate NDA unnecessary for that transfer.

    What is the standard material transfer agreement?

    There is no single global standard MTA. The closest equivalent is the US Uniform Biological Material Transfer Agreement (UBMTA), a pre-agreed master framework maintained by AUTM. UK institutions instead draft from Lambert Toolkit model clauses or their own institutional precedent, negotiating each transfer individually.

    What is the purpose of an MTA?

    An MTA’s purpose is to regulate the use and distribution of transferred material, define legal provisions such as warranties, indemnities and risk allocation, specify each party’s access to results, and settle ownership of any resulting intellectual property and publication rights.

    What this means for research offices

    Material transfer volumes are rising as biological data-sharing mandates and open-research policies push more labs to exchange materials alongside associated datasets. As funders increasingly expect materials and data underlying published results to be shareable, research offices should expect MTA review queues — and negotiation over restrictive provider terms — to keep growing rather than shrink. Building clause-level familiarity now, rather than treating every incoming MTA as a bespoke legal puzzle, is the most efficient way for a research administration office to keep transfers moving without exposing the institution to unmanaged IP or liability risk.

  • UK Research Funding Volatility 2026: Key Signals

    UK research funding volatility 2026 refers to the disruption research offices are managing this year as UK Research and Innovation (UKRI) replaces its council-by-council allocation model with a new three-part “buckets” structure, pauses several applicant-led grant routes, and holds discretionary research funding flat in cash terms while overall spending rises. For research administrators, the practical effect is a period of scheme-by-scheme uncertainty layered on top of institutional financial strain.

    Research funding volatility, in this context, is the combination of budget reallocation, temporary application pauses, and system migration that makes it harder for a research office to predict which schemes will be open, on what terms, and on what platform, in any given month of 2026.

    Contents

    Why Is UK Research Funding Volatile in 2026?

    UK research funding volatility in 2026 stems from three overlapping pressures hitting research offices simultaneously. UKRI is mid-way through a multi-year restructuring of how it allocates money between now and 2030. Several research councils have paused or reopened applicant-led grant routes within months of each other. And university finances are already stretched, so any funder-side disruption lands on institutions with little slack to absorb it.

    The Russell Group reports that 45% of English higher education providers are forecasting a deficit for the 2025/26 financial year, with universities in Wales, Scotland and Northern Ireland facing even more acute pressure. Against that backdrop, a paused grant call or a delayed platform migration is not a minor administrative inconvenience — it is a cash-flow and workforce-planning risk for the office managing it.

    How Is UKRI Restructuring Its Funding Model?

    From April 2026, UKRI has organised its budget into three funding “buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies. This replaces the previous council-led allocation logic with a cross-cutting structure intended to make funding priorities more explicit and outcome-focused.

    UKRI’s own December 2025 budget-allocations explainer confirms that the organisation’s total research and innovation budget is on a path to rise towards £10 billion a year by 2030, even as the mix shifts. Sector analysis published by Wonkhe on the CEO’s budget mapping, and coverage by the Institute of Physics, both describe discretionary curiosity-driven funding as held flat in cash terms over the same period — a real-terms reduction once inflation is applied, even as strategic-priority and innovation-linked funding lines grow.

    • Curiosity-driven research: open, investigator-led schemes; budget held broadly flat in cash terms into the near future.
    • Strategic priorities: government- and society-aligned mission funding, expected to absorb a growing share of the uplift.
    • Innovative companies: commercialisation and translation funding routed largely through Innovate UK.

    UKRI’s Chief Executive, Professor Sir Ian Chapman, confirmed to the House of Commons Science, Innovation and Technology Committee in March 2026 that the organisation will publish a new single delivery plan for the 2026/27 financial year, intended to give the sector its first detailed, comparable view of spending under the new bucket model.

    Which Funding Pauses and Cuts Have Hit Research Offices?

    Alongside the structural changes, individual councils have paused or reduced specific routes. According to analysis by the Campaign for Science and Engineering (CaSE), published in February 2026, three research councils — the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC) — paused applicant-led grant routes in the same period, while the Science and Technology Facilities Council (STFC) began cost reductions driven by rising international subscription costs.

    UKRI’s own “Pauses to funding opportunities” tracking page, last updated in June 2026, confirms that BBSRC’s applicant-led routes were paused while the council moved to an “always open” application model, and that the affected opportunities have since reopened. The table below summarises the position reported across these sources.

    Council / route 2026 development Reported driver
    MRC — applicant-led grants Paused, then phased reopening Transition to new UKRI funding model
    BBSRC — applicant-led grants Paused, reopened by mid-2026 Move to an “always open” application system
    EPSRC — selected routes Paused for review Alignment with the three-bucket structure
    STFC — facilities & subscriptions Cost reductions, some projects shelved Rising international subscription costs

    For research offices, the operational consequence is that a scheme’s status cannot be assumed stable from one funding round to the next. Pre-award teams need to check live status on each council’s page rather than relying on a static internal calendar.

    What Should Research Offices Do to Prepare?

    ARMA — the UK’s professional association for research leadership, management and administration, with member representation from across the higher education and broader research sector — has used its Spring 2026 news round-ups to flag exactly this combination of themes: funding volatility, UKRI’s restructuring, and the practical burden falling on institutional research offices. Read together, the signals point to a small number of concrete readiness actions.

    • Track pause and reopening status directly on funder pages rather than relying on cached internal deadline lists, given how quickly routes have reopened or shifted in 2026.
    • Build strategic-alignment framing into proposal support, since a larger share of new funding is routed through the strategic-priorities and innovation buckets rather than open curiosity-driven calls.
    • Plan for a hybrid systems period as UKRI continues migrating applications from its legacy Joint Electronic Submission (Je-S) system to the newer UKRI Funding Service, with some schemes on each platform simultaneously.
    • Prepare for tighter data and identifier requirements, including consistent use of ORCID iDs, as UKRI’s funding service standardises applicant and organisation data.
    • Model cash-flow scenarios against institutional deficit risk, given the Russell Group’s finding that close to half of English providers are already forecasting a 2025/26 deficit.

    None of this requires guessing at UKRI’s intentions. UKRI has published its own budget-allocation explainer and a live pauses-tracking page, and has committed to a single delivery plan for 2026/27 — the readiness task for research offices is to build monitoring habits around those existing, funder-published sources rather than waiting for a single announcement.

    Answer-First Q&A For Research Administrators

    What Is the Role of a Research Administrator in This Transition?

    A research administrator prepares and submits grant applications, tracks budgets, ensures compliance with funder terms, and manages awards through their lifecycle. During UKRI’s 2026 restructuring, that role expands to include monitoring live pause/reopening status across councils and translating shifting funding buckets into realistic advice for principal investigators.

    What Skills Do Research Administrators Need Now?

    Beyond core pre- and post-award skills, 2026 places a premium on funder-monitoring discipline, strategic framing of proposals against national priorities, and comfort operating two parallel application systems at once. Research offices report that data-governance literacy — particularly around ORCID and standardised identifiers — is becoming a distinct, named competency rather than a background task.

    What Is UKRI’s New Funding Service?

    The UKRI Funding Service is the platform UKRI is migrating applicants to from its legacy Je-S system, intended to standardise and simplify submissions across councils. Through 2026 the two systems run in parallel, so research offices must confirm on a scheme-by-scheme basis which platform a given call uses before advising applicants.

    When Will UKRI Publish Its Next Delivery Plan?

    UKRI’s Chief Executive confirmed to Parliament’s Science, Innovation and Technology Committee in March 2026 that a single delivery plan covering the 2026/27 financial year is in preparation. This is expected to give the sector its first detailed, comparable breakdown of spending under the new three-bucket model.

    What This Means for the Sector Going Forward

    The direction of travel is toward a more strategically aligned, outcome-focused UKRI, not a shrinking one — the headline budget is rising even as its composition changes. That distinction matters for research offices: the volatility is concentrated in which routes are open and on what terms, not in an overall retreat from UK research funding.

    Institutions that treat 2026 as a year of active funder-monitoring, rather than a wait for stability to return, are better placed to advise researchers accurately. Research offices that build the habit of checking UKRI’s published pauses tracker and budget explainer directly, and that read ARMA’s sector round-ups for cross-institutional context, will be positioned to respond as the 2026/27 delivery plan clarifies the practical detail behind the bucket model.

  • UK University Redundancies Hit Research Support Capacity

    UK university redundancies are accelerating through 2026 as institutional funding deficits force cost-cutting across the sector, and a disproportionate share of the job losses is falling on research offices — the grants-management, costing and research-development staff who support academics through funding applications, compliance and post-award administration. The result is a quiet but measurable shrinkage in the specialist capacity that keeps UK research income flowing.

    A university redundancy round is a formal consultation and job-cut process — covering both academic and professional-services roles — that an institution undertakes when trustees judge continued financial deficits unsustainable without headcount reduction. In 2026, that process is playing out simultaneously at dozens of UK institutions.

    What is driving the 2026 redundancy wave

    The immediate trigger is financial. The Office for Students‘ 2026 financial sustainability report found that 36% of English higher-education providers reported a deficit in their 2024-25 accounts, and the regulator now forecasts that more than four in ten will do so in 2026-27. Frozen domestic tuition fees, a sharp fall in international student recruitment following tighter visa and dependant-route rules, and rising employer National Insurance costs have combined to squeeze budgets that many institutions had structured around cross-subsidy from overseas fee income.

    Data aggregated by the Destination for Education coalition — representing six international-pathway providers — and reported by The PIE News shows more than 5,000 redundancies announced across over 20 UK institutions between 2025 and 2026, spanning both teaching and professional-services staff. The University and College Union has separately tracked redundancy or restructuring processes under way at roughly 30 institutions by mid-2026.

    Recent examples illustrate the scale:

    Institution Roles affected Stated savings target Reported driver
    University of Nottingham ~2,700 staff at risk; 609 posts targeted Addressing a reported deficit “Significant financial challenges” (BBC, Guardian, 12 May 2026)
    University of Sussex 200+ further roles (after 528 in the prior year) £35m annually Falling student numbers, 45-day consultation opened June 2026
    Sheffield Hallam University 130+ roles ~£27m Restructuring plan; 18 days of UCU strike action
    University of Aberdeen 100+ roles £10m Sector-wide savings drive

    How the cuts are landing on research offices and grants management

    Redundancy rounds are rarely confined to academic departments. Professional-services teams — including the research and innovation offices responsible for grant development, costing, contracts and post-award compliance — have featured in several 2026 restructuring proposals. Specialist recruiters and research-management commentators report that grant-development and research-support posts have in some cases been cut alongside, rather than protected from, wider professional-services reductions.

    The consequences are most visible at Nottingham, where the University and College Union warned that cutting 609 posts “poses systemic risks to research” and risks “intellectual stagnation” at one of the UK’s most research-intensive universities, according to Research Professional News (13 May 2026). When grants officers and research-development managers are cut, the administrative load does not disappear — it shifts onto remaining professional-services staff and onto academics themselves, who have less time for the grant-writing and horizon-scanning that generates future research income.

    Times Higher Education’s UK University Redundancy Survey, published in 2026, quantifies the knock-on effect on those who remain: 87% of respondents said workloads increased for surviving staff after colleagues were made redundant, and up to 9,000 staff across the sector’s 165 institutions have been affected by compulsory redundancies. For research offices specifically, this typically means:

    • Fewer dedicated staff available to support complex, multi-partner or international grant applications
    • Longer turnaround times for costing, due-diligence and contract review ahead of funder deadlines
    • Reduced capacity for post-award compliance monitoring, increasing the risk of funder non-compliance findings
    • Institutional knowledge loss, as experienced research-development managers — Times Higher Education found 57% of redundant staff had held their last role for more than a decade — leave the sector

    Answer-first Q&A

    Which universities have announced redundancies in 2026?

    By mid-2026 the University and College Union was tracking redundancy or restructuring processes at roughly 30 UK institutions, including the University of Nottingham (609 posts), University of Sussex (200+ further roles), Sheffield Hallam University (130+ roles) and the University of Aberdeen (100+ roles), alongside dozens of smaller consultations sector-wide.

    Why are universities making staff redundant?

    Institutions cite frozen domestic tuition fees, falling international student recruitment after visa and dependant-route restrictions, and rising staff costs. The Office for Students found 36% of English providers recorded a deficit in 2024-25, with more than four in ten forecast to do so in 2026-27, forcing cost-cutting across academic and professional-services roles.

    Which UK universities are in financial trouble in 2026?

    The Office for Students‘ 2026 financial sustainability report found over a third of English providers in deficit, with research-intensive universities including Nottingham, Sussex, Dundee and Cardiff among those confirming restructuring, redundancy consultations or strike action tied to 2026 budget shortfalls.

    What shrinking research support means for institutions and funders

    For research administrators, the practical effect of these cuts is a capacity gap that does not track neatly onto headline redundancy numbers. A university can report a modest reduction in professional-services headcount overall while losing a much larger share of its specialist grants-management expertise, because research-development roles are typically small teams to begin with. Losing two or three experienced research-development managers from a team of six is proportionally far more damaging than the same absolute cut spread across a 200-person estates or IT department.

    This matters beyond the institutions directly affected. Funders including UKRI and participants in Horizon Europe rely on institutional research offices to deliver compliant, well-costed applications and to manage post-award reporting. A sector-wide thinning of that layer raises the practical risk of slower application turnaround, weaker costing on complex bids, and delayed or incomplete compliance reporting — outcomes that affect funders’ administrative burden as much as universities’ own income. Research administration bodies such as ARMA, NCURA, EARMA and INORMS have long argued that professional research-management capacity is a determinant of research quality and funding success, not merely an overhead line to be trimmed in a downturn.

    Outlook: what happens next

    The Office for Students’ own forecast — more than four in ten English providers in deficit by 2026-27 — suggests this redundancy wave has not yet peaked. Institutions still working through consultations, including Sussex and Sheffield Hallam, are likely to be followed by further rounds elsewhere as the sector absorbs the combined effect of frozen fees and reduced international recruitment. For research offices, the immediate priority is protecting the specialist grants-management and compliance functions that are disproportionately hard to rebuild once lost, since experienced research-development staff — many with a decade or more in post, per the Times Higher Education survey — are not readily replaced on short notice. How institutions balance short-term savings against this longer-term research-capacity cost will shape the UK’s competitiveness for external funding well beyond the current financial year.

    For background on how research offices are typically structured and resourced, see CASRAI’s research administration resources.

  • UKRI AI Research Labs: What They Mean for Grant Applicants

    UKRI has committed up to £60 million to two new AI research labs, SOFAIR and BOLD, led by UCL and the University of Oxford and funded through the Engineering and Physical Sciences Research Council (EPSRC). For grant applicants, the announcement signals a shift toward fundamental, open-source AI research, cross-institution consortium bidding, and a staged, assessment-gated funding model that is likely to shape future UKRI AI calls across all seven research councils.

    UKRI’s AI research labs are strategic, multi-year research centres — the first major investment released under UKRI’s AI Strategic Framework — built to fund high-risk, high-reward fundamental AI research rather than applied product development. The two labs were announced on 23 June 2026, timed to coincide with what would have been Alan Turing’s 114th birthday.

    What are UKRI’s new AI research labs?

    UKRI’s two new labs are the Science of Fundamental AI Research (SOFAIR) Lab, led by UCL, and the British Open-ended Learning and Discovery (BOLD) Lab, led by the University of Oxford. Both are funded through EPSRC, the UKRI council responsible for engineering and physical sciences, and both work across consortium partners rather than a single institution.

    SOFAIR brings together UCL with the universities of Cambridge, Oxford and Edinburgh to develop next-generation open-source AI architectures that can run on widely available hardware, reducing dependence on a small number of proprietary model providers. It is led by Professor David Barber of UCL. BOLD, led by Associate Professor Jakob Foerster of Oxford, works with UCL and Imperial College London on new learning paradigms — human-centred AI, embodied systems and learning without vast centralised compute.

    Feature SOFAIR Lab BOLD Lab
    Lead institution UCL University of Oxford
    Lead investigator Professor David Barber Associate Professor Jakob Foerster
    Consortium partners Cambridge, Oxford, Edinburgh UCL, Imperial College London
    Core focus Open-source AI on accessible hardware New learning paradigms, embodied AI
    Initial funding released ~£8 million ~£8 million
    Doctoral training ring-fence £2 million (min. 10 students) £2 million (min. 10 students)

    Why did UKRI double the investment to £60 million?

    UKRI’s original plan committed £40 million to a single AI research lab. The final announcement doubled the number of labs to two and lifted total committed funding to up to £60 million — a signal that the review panel judged the applicant pool strong enough to fund parallel, competing research directions rather than consolidate around one.

    Each lab initially receives around £8 million, with the remainder of its allocation released only after an assessment in autumn 2026. This staged, gated funding model — rather than a single upfront grant — is itself a departure from how UKRI has typically structured large capital-style research investments, and it is a detail every institution bidding into future rounds should note.

    What does this mean for grant applicants?

    For institutions and principal investigators watching UKRI’s AI funding pipeline, four practical signals stand out:

    • Consortium bids are favoured over single-institution proposals. Both labs span three to four universities, reflecting UKRI’s preference for pooled expertise over isolated centres of excellence.
    • Fundamental, “blue-sky” research is explicitly back in favour. EPSRC’s framing prioritises foundational questions — new architectures, new learning algorithms — over applied deployment work, reversing some of the recent emphasis on near-market translation.
    • Doctoral and early-career funding is ring-fenced, not discretionary. Each lab must support a minimum of ten doctoral students from a dedicated £2 million allocation, giving PhD applicants and postdocs a concrete, quantifiable funding route rather than a vague promise of “opportunities.”
    • Continuation funding is now conditional on a mid-point review. Applicants should expect future large AI awards to build in an autumn-style assessment gate before releasing full committed funding, rather than disbursing the full sum at award.

    Open-source commitments and spin-out support are also written into both labs’ remits, so institutions preparing future bids should be ready to demonstrate a route to commercialisation and public dissemination of tooling, not only publication output.

    How does this fit UKRI’s cross-council AI strategy?

    EPSRC administers the SOFAIR and BOLD awards, but the labs sit inside a wider, cross-council AI programme. UKRI comprises seven research councils, and the AI Strategic Framework explicitly positions AI as a cross-cutting priority rather than an EPSRC-only remit. The Science and Technology Facilities Council (STFC) — best known for its Hartree Centre, which provides supercomputing and applied AI infrastructure to UK researchers and industry — sits alongside EPSRC as part of that same seven-council structure, underscoring that compute infrastructure and fundamental AI research are being coordinated as complementary strands of one strategy rather than funded in isolation.

    Professor Charlotte Deane, Senior Responsible Owner for the UKRI AI Programme and Executive Chair of EPSRC, described the labs as backing “the bold, high-reward ideas that can shape the future of AI” — language that maps directly onto UKRI’s broader AI strategy documents, which call for regional clusters, sovereign compute capability and closer links between fundamental research councils and applied infrastructure providers such as STFC and the Alan Turing Institute.

    Frequently asked questions

    What is the UKRI AI strategy plan?

    UKRI’s AI strategy sets out a plan to turn the UK’s research strengths into economic advantage by backing fundamental AI research, regional innovation clusters and sovereign AI capability. The SOFAIR and BOLD labs are described as the first major investment released under this framework, with further AI calls expected to follow the same fundamental-research emphasis.

    How much funding did UKRI commit to the new AI labs?

    UKRI committed up to £60 million across the two labs, doubling an original £40 million single-lab plan. Each lab receives an initial tranche of roughly £8 million, with the remaining funds released after an autumn 2026 progress assessment.

    Can researchers outside UCL and Oxford apply for lab funding?

    The two labs are led by UCL and Oxford with named consortium partners, so direct lab leadership is fixed. However, doctoral studentships, postdoctoral posts and collaboration opportunities are expected to open as the labs recruit, and researchers should monitor EPSRC and UKRI funding-opportunity pages for associated calls.

    Which universities lead UKRI’s new AI research labs?

    UCL leads the SOFAIR Lab with Cambridge, Oxford and Edinburgh as partners; the University of Oxford leads the BOLD Lab with UCL and Imperial College London as partners. Both labs also engage with the Alan Turing Institute and UKRI’s existing AI research hubs.

    Implications and outlook

    For research administrators drafting institutional AI strategies, the SOFAIR and BOLD awards are a useful template for what UKRI now expects from a competitive large-scale AI bid: multi-institution consortia, an explicit open-source or public-good deliverable, a ring-fenced doctoral-training component, and acceptance of a staged funding gate rather than a single lump-sum award.

    The autumn 2026 assessment point is worth diarising directly — it will be the first public test of whether UKRI’s gated model releases the remaining funds smoothly or triggers a public renegotiation, and either outcome will inform how future large AI calls from EPSRC, and potentially jointly with STFC’s compute-infrastructure remit, are structured. Institutions preparing bids for the next round of UKRI AI funding should treat this announcement as the current baseline for what “fundable” fundamental AI research now looks like in the UK.

  • UK R&D Investment 2026: Grant Pipeline Impact for Institutions

    The UK government has committed £55.4 billion in detailed Department for Science, Innovation and Technology (DSIT) research and development allocations for the financial years 2026/27 to 2029/30, part of a wider £58.5 billion real-terms R&D budget for the period. UK Research and Innovation (UKRI) alone will deliver £38.6 billion of that total, rising to nearly £10 billion a year by 2029/30. For research administrators, the practical question is not the headline figure but what it does to grant pipelines, funder call volumes, and institutional planning cycles over the next four years.

    UK research and development investment 2026 refers to the multi-year DSIT and UKRI budget settlement, published 30 October 2025, that sets funding envelopes for UK public research bodies from 2026/27 through 2029/30. This is a spending-review allocation, not a single-year grant round — and that distinction shapes how institutions should plan.

    Contents

    What is changing in UK R&D investment for 2026?

    DSIT’s overall R&D budget will grow in real terms across the current Spending Review period, reaching £58.5 billion between 2026/27 and 2029/30, according to the department’s published R&D plans. Of that total, £55.4 billion has been allocated in detail across named organisations and programmes, with the remainder — covering programmes still being finalised — to be confirmed later.

    This is a multi-year settlement rather than a single Budget announcement. It replaces annual uncertainty with a four-year envelope, which changes how institutions can realistically plan grant-writing capacity, co-investment commitments, and infrastructure bids.

    How is the £55.4bn allocation broken down by organisation?

    UKRI is the largest single recipient, with an expected £38.6 billion across the four years — its budget rising from £8.811 billion in 2025/26 to £9.986 billion in 2029/30. A more detailed breakdown of UKRI’s own council-level budgets followed in December 2025. The remaining allocation is split across UK contributions to EU programmes (including Horizon Europe and its successor), the UK Space Agency, the Met Office, the Advanced Research and Invention Agency (ARIA), the National Academies, the Office for Life Sciences, the National Measurement System, and the AI Security Institute (AISI).

    Organisation / programme 2025/26 (£m) 2029/30 (£m) Total 2026/27–2029/30 (£m)
    UK Research and Innovation (UKRI) 8,811 9,986 38,586
    UK contribution to EU programmes 2,736 2,200 8,716
    UK Space Agency 668 720 2,798
    Met Office 310 347 1,467
    ARIA 184 400 1,220
    Office for Life Sciences 129 146 925
    National Academies 217 235 910
    National Measurement System 130 145 558
    AI Security Institute (AISI) 66 60 240

    Source: DSIT, “Research and Development (R&D) plans to 2029/2030”, published 30 October 2025. Figures are planning allocations and, per DSIT’s own disclaimer, subject to in-year reallocation under its new “agile” budget-management approach.

    What does this mean for institutional grant pipelines?

    A rising, multi-year UKRI envelope — from £9.220 billion in 2026/27 to £9.986 billion by 2029/30 — gives research offices a firmer basis for forward-loading grant pipelines than the single-year settlements common in prior spending rounds. Institutions can use the published trajectory to model realistic co-investment and matched-funding exposure three to four years out, rather than reacting to annual uncertainty.

    DSIT itself frames its new approach as more agile: funding can move across financial years where projects are delayed, be reallocated where a programme underspends, or be deprioritised where it is not delivering. That flexibility cuts both ways for pipeline planning — a confirmed four-year envelope is more predictable in total, but individual scheme budgets within it may shift year to year as DSIT and UKRI reprioritise.

    • Build grant-pipeline forecasts around the confirmed multi-year UKRI trajectory, not single-year headline figures.
    • Track the UK contribution to EU programmes carefully — it falls from £2.736 billion (2025/26) to £2.121 billion (2026/27) as Horizon Europe Guarantee costs wind down, which affects institutions relying on guarantee-funded EU collaborations.
    • Monitor ARIA’s rapid growth (from £184 million to £400 million across the period) as a distinct, high-risk/high-reward funding route worth separate pipeline tracking from mainstream UKRI council schemes.

    Will funder call volumes and success rates change?

    UKRI’s own overall research and innovation budget is confirmed as rising during this Spending Review period, reaching almost £10 billion annually by 2030. A rising overall envelope does not automatically translate into proportionally more open calls — much depends on how UKRI’s nine councils allocate the increase between responsive-mode schemes, strategic priority programmes, and infrastructure.

    DSIT has stated three explicit R&D priorities guiding allocation: protecting curiosity-driven, foundational science; supporting strategic government and societal priorities; and targeting innovative, UK-based company scale-up and growth. Research administrators should expect call volumes to grow unevenly across these three streams rather than uniformly across all disciplines.

    Answer-first questions research administrators are asking

    What is the UK government’s total R&D budget for 2026/27?

    DSIT’s overall R&D budget totals £58.5 billion across 2026/27–2029/30, with £55.4 billion of that detailed by organisation in DSIT’s published plans as of 30 October 2025. UKRI is the largest single component, at £38.6 billion over the same four years.

    How much has UKRI’s budget increased?

    UKRI’s budget rises from £8.811 billion in 2025/26 to £9.220 billion in 2026/27, reaching £9.986 billion by 2029/30 — an increase of roughly £1.18 billion, or 13%, across the Spending Review period, per DSIT’s published allocation table.

    Why is the UK’s EU programme contribution falling?

    The UK’s contribution to EU programmes, including Horizon Europe, drops from £2.736 billion in 2025/26 to £2.121 billion in 2026/27 as Horizon Europe Guarantee costs wind down and the UK’s automatic correction mechanism under its association agreement takes effect, per DSIT.

    What return does public R&D investment generate?

    DSIT’s research states that each pound of public R&D investment leverages, on average, £2 of private R&D investment and generates £8 of net benefit in the long run, citing its “Value of Public R&D” research report (DSIT 2025/036).

    What should research offices do now?

    Institutional research offices, grants teams, and pro-vice-chancellors for research should treat this settlement as a four-year planning input rather than a one-off announcement.

    1. Re-baseline internal grant-pipeline forecasts against the confirmed year-by-year UKRI figures rather than the single £55.4 billion or £38.6 billion headline totals.
    2. Flag EU-programme-dependent projects for early review given the falling Horizon Europe Guarantee allocation.
    3. Build ARIA into distinct pipeline tracking, separate from mainstream UKRI responsive-mode schemes, given its faster proportional growth.
    4. Watch for UKRI’s own council-level budget detail and DSIT’s in-year reallocation decisions, since both bodies have flagged an “agile” approach that can shift funding between years and schemes.

    Outlook: the next four years

    The confirmed trajectory to nearly £10 billion in annual UKRI funding by 2029/30, inside a wider £58.5 billion DSIT envelope, gives UK research administration a rare degree of multi-year visibility. The practical work now shifts from interpreting the headline figure to modelling how each council, scheme, and international programme within it will move — a task best served by revisiting institutional grant-pipeline forecasts against DSIT’s published tables rather than summary press coverage. Sound research administration practice in this period means tracking these allocations at the same granularity DSIT itself now publishes them.